2026. A NOVEL RNA INTERFERENCE THERAPY TO REDUCE CARDIOVASCULAR RISK BY LOWERING LIPOPROTEIN(A) LEVELS USING THE LEPODISIRAN AGENT. Journal of Multidisciplinary Sciences and Innovations. 5, 03 (Mar. 2026), 1550–1553. DOI:https://doi.org/10.55640/.